AIP
NBIX icon

Ameritas Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Ameritas Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Hold
18,489
– – 0.08% 237
2026
Q1 		$2.44M Buy
18,489
+216
+1% +$28.7K 0.07% 273
2025
Q4 		$2.59M Sell
18,273
-319
-2% -$46.2K 0.08% 255
2025
Q3 		$2.61M Sell
18,592
-623
-3% -$84.4K 0.08% 258
2025
Q2 		$2.42M Sell
19,215
-402
-2% -$46.1K 0.08% 263
2025
Q1 		$2.17M Sell
19,617
-662
-3% -$83.9K 0.07% 289
2024
Q4 		$2.77M Sell
20,279
-437
-2% -$54K 0.09% 216
2024
Q3 		$2.39M Sell
20,716
-689
-3% -$94.5K 0.08% 270
2024
Q2 		$2.95M Sell
21,405
-538
-2% -$73.8K 0.1% 191
2024
Q1 		$3.03M Buy
21,943
+249
+1% +$34K 0.1% 194
2023
Q4 		$2.86M Sell
21,694
-207
-0.9% -$23.8K 0.1% 185
2023
Q3 		$2.46M Sell
21,901
-2,466
-10% -$260K 0.1% 200
2023
Q2 		$2.3M Sell
24,367
-223
-0.9% -$21.8K 0.09% 244
2023
Q1 		$2.49M Sell
24,590
-290
-1% -$30.2K 0.1% 212
2022
Q4 		$2.71M Buy
24,880
+284
+1% +$33.3K 0.11% 192
2022
Q3 		$2.61M Sell
24,596
-769
-3% -$78K 0.12% 156
2022
Q2 		$2.47M Hold
25,365
– – 0.11% 185
2022
Q1 		$2.38M Hold
25,365
– – 0.09% 256
2021
Q4 		$2.16M Buy
25,365
+294
+1% +$27K 0.07% 304
2021
Q3 		$2.4M Sell
25,071
-484
-2% -$45.7K 0.09% 243
2021
Q2 		$2.49M Sell
25,555
-245
-0.9% -$23.5K 0.09% 252
2021
Q1 		$2.51M Buy
+25,800
New +$2.71M 0.1% 230
2016
Q2 		– Sell
-6,662
Closed -$263K – 1189
2016
Q1 		$263K Hold
6,662
– – 0.02% 850
2015
Q4 		$377K Buy
6,662
+70
+1% +$3.56K 0.03% 694
2015
Q3 		$262K Hold
6,592
– – 0.02% 818
2015
Q2 		$315K Sell
6,592
-853
-11% -$36.2K 0.02% 791
2015
Q1 		$296K Buy
+7,445
New +$266K 0.02% 833

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameritas Investment Partners's NBIX Position: Q2 2026 in Review

Ameritas Investment Partners held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 18,489 shares worth $3.12M. The position accounts for 0.08% of the portfolio, ranked #237.

Ameritas Investment Partners first reported a position in NBIX in Q1 2015 and has held it in 27 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ameritas Investment Partners held 18,489 shares of Neurocrine Biosciences worth $3.12M as of Q2 2026.
  • Ameritas Investment Partners left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.08% of Ameritas Investment Partners's portfolio in Q2 2026, its #237 holding.
  • Ameritas Investment Partners first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 27 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.